Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

S'inscrire

CELZ Creative Medical Technology Holdings Inc

4,39

0,0899 (2,09%)

Dernière mise à jour : 15:45:55

Retardé de 15 minutes

Biotech Finds Mid-Week Success Following FDA Announcement

A biotech company that is no stranger to coming across our desk has made headlines yet again after it was announced the company received orphan drug...

To read the full story on AllPennyStocks.com, click here.

Creative Medical Technol... (NASDAQ:CELZ)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024

Plus de graphiques de la Bourse Creative Medical Technol...

Creative Medical Technol... (NASDAQ:CELZ)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024

Plus de graphiques de la Bourse Creative Medical Technol...

Actualités Creative Medical Technology Holdings Inc

Form 8-K - Current report
Vendredi 17 Mai 2024 ( il y a 4 jours) • Edgar (US Regulatory)

Form PRE 14A - Other preliminary proxy statements
Vendredi 17 Mai 2024 ( il y a 4 jours) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Vendredi 10 Mai 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Creative Medical Technology Holdings Provides Corporate Update
Mercredi 27 Mars 2024 ( il y a 2 mois) • Business Wire

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
Jeudi 7 Mars 2024 ( il y a 2 mois) • Business Wire

Biotech Finds Mid-Week Success Following FDA Announcement
Mercredi 6 Mars 2024 ( il y a 2 mois) • AllPennyStocks.com

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
Mercredi 6 Mars 2024 ( il y a 3 mois) • Business Wire

Form 8-K - Current report
Mercredi 20 Décembre 2023 ( il y a 5 mois) • Edgar (US Regulatory)

Creative Medical Technology Holdings Provides Corporate Update
Mercredi 15 Novembre 2023 ( il y a 6 mois) • PR Newswire (US)

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain
Mardi 10 Octobre 2023 ( il y a 7 mois) • PR Newswire (US)

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain
Mardi 19 Septembre 2023 ( il y a 8 mois) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Vendredi 11 Août 2023 ( il y a 9 mois) • Edgar (US Regulatory)

Plus d'articles sur Creative Medical Technology Holdings Inc

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales